Skip to main content

News

  • Press Releases
  • Presentations & Publications
  • In The News
November 2, 2023
Phase 1 Study of IDRX-42 in Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Prior Systemic Therapy: Early Results
Read More
May 24, 2023
Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)
Read More
February 2, 2023
Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors
Read More
November 18, 2022
Anti-tumor Effects of the Novel KIT Inhibitor IDRX-42 (formerly M4205) in Gastrointestinal Stromal Tumor (GIST) Xenograft Models
Read More
September 28, 2022
Anti-tumor effects of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell lined-derived xenograft models of gastrointestinal stromal tumor (GIST)
Read More
Intelligently Designed Precision Therapies to Transform Cancer Care
info@idrx.com
careers@idrx.com
media@idrx.com
  • Our Approach
  • Who We Are
  • Patients
  • Press Releases
© 2023 IDRx Inc. Privacy Policy. Terms of Use.